RANI — Rani Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00- $15.20m
- -$29.44m
- $1.63m
Brief: Rani Therapeutics Q4 Operating Expenses USD 15.986 Million
Rani Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary
Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102
Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview
Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery Of Semaglutide Via Ranipill HC
Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary
Rani Therapeutics Holdings Inc expected to post a loss of 26 cents a share - Earnings Preview
Rani Therapeutics Holdings Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery Of GLP-1 Incretin Triagonist
Brief: Rani Therapeutics Announces Pricing Of $10 Mln Registered Direct Offering
Brief: Rani Therapeutics Says Co Had Recently Engaged In Discussions With Various Investors To Explore A Potential Equity Financing
Brief: Rani Therapeutics Announces Partnership With Progen
Rani Therapeutics Holdings Inc reports results for the quarter ended in December - Earnings Summary
Rani Therapeutics Holdings Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Rani Therapeutics Announces Positive Topline Results From Phase 1 Study Of An Oral Anti-Interleukin 12/23 Antibody
Brief: Rani Therapeutics Announces Preclinical Pharmacodynamic Data On Transenteric Delivery Of GLP-1 Incretin Triagonist
Brief: Rani Therapeutics Announces Successful Oral Delivery Of Monoclonal Antibody Via High-Capacity Pill In Preclinical Study